US 10238659
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
granted A61KA61K31/513A61P
Quick answer
US patent 10238659 (Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists) held by Corcept Therapeutics Incorporated expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/513, A61P, A61P1/16